Amelioration of glomerulosclerosis with all-trans retinoic acid is linked to decreased plasminogen activator inhibitor-1 and α-smooth muscle actin

Acta Pharmacologica Sinica

Volumn 32, Issue 1, 2011, Pages 70-78

  Liu, Xia ^a,b   Lü, Lei ^a   Tao, Bei Bei ^a   Zhou, Ai Ling ^b   Zhu, Yi Chun ^a  

^a FUDAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

smooth muscle actin; nephrectomy; plasmin; plasminogen activator inhibitor 1; retinoids

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CREATININE; GELATINASE A; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY STRUCTURE; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; URINARY EXCRETION;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; BODY WEIGHT; FIBRINOLYSIN; GENE EXPRESSION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY; KIDNEY DISEASES; MALE; MATRIX METALLOPROTEINASE 2; NEPHRECTOMY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; TRETINOIN;

EID: 78651103064     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.200     Document Type: Article

References (56)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56.
2. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-35.
3. Johnson RJ, Floege J, Yoshimura A, Iida H, Couser WG, Alpers CE. The activated mesangial cell: A glomerular "myofibroblast"? J Am Soc Nephrol 1992; 2: S190-7.
4. Zhang G, Moorhead PJ, el Nahas AM. Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol 1995; 3: 308-18.
5. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991; 87: 847-58.
6. Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997; 12: 904-15.
7. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-20.
8. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-7.
9. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, et al. Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005; 67: 2221-38.
10. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, et al. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1487-95.
11. Oda T, Jung YO, Kim HS, Cai X, López-Guisa JM, Ikeda Y, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60: 587-96.
12. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005; 67: 1297-307.
13. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006; 69: 1064-72.
14. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L. Plasminogen activator inhibitor-1 gene deficiency attenuates TGFbeta1- induced kidney disease. Kidney Int 2005; 68: 2651-66.
15. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-88.
16. Omasu F, Oda T, Yamada M, Yoshizawa N, Yamakami K, Sakurai Y, et al. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am J Physiol Renal Physiol 2007; 293: F1292-8.
17. Heidland A, Sebekova K, Paczek L, Teschner M, Dämmrich J, Gaciong Z. Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney Int Suppl 1997; 62: S32-5.
18. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
19. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995; 47: 1039-47.
20. Adams J, Kiss E, Arroyo AB, Bonrouhi M, Sun Q, Li Z, et al. 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol 2005; 167: 285-98.
21. Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004; 82: 568-76.
22. Schaier M, Jocks T, Grone HJ, Ritz E, Wagner J. Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol 2003; 170: 1398-402.
23. Suzuki A, Ito T, Imai E, Yamato M, Iwatani H, Kawachi H, et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003; 14: 981-91.
24. Vaughan MR, Pippin JW, Griffin SV, Krofft R, Fleet M, Haseley L, et al. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005; 68: 133-44.
25. Wagner J, Dechow C, Morath C, Lehrke I, Amann K, Waldherr R, et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000; 11: 1479-87.
26. Dechow C, Morath C, Peters J, Lehrke I, Waldherr R, Haxsen V, et al. Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol 2001; 281: F909-19.
27. Morath C, Ratzlaff K, Dechow C, Schwenger V, Schaier M, Zeier B, et al. Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized rats. J Mol Med 2009; 87: 53-64.
28. Morath C, Dechow C, Lehrke I, Haxsen V, Waldherr R, Floege J, et al. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12: 2300-9.
29. Lü L, Yao T, Zhu YZ, Huang GY, Cao YX, Zhu YC. Chronic all-trans retinoic acid treatment prevents medial thickening of intramyocardial and intrarenal arteries in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003; 285: H1370-7.
30. Liu X, Lü L, Tao BB, Zhu YC. All-trans retinoic acid inhibits the increases in fibronectin and PAI-1 induced by TGF-beta1 and Ang II in rat mesangial cells. Acta Pharmacol Sin 2008; 29: 1035-41.
31. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-43.
32. Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 2000; 11: 497-506.
33. Gonçalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, et al. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: Strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286: F945-54.
34. Ljutic D, Kes P. The role of arterial hypertension in the progression of non-diabetic glomerular diseases. Nephrol Dial Transplant 2003; 18: V28-30.
35. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43: 346-53.
36. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
37. Shankland SJ. The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-47.
38. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 2004; 13: 31-7.
39. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995; 96: 953-64.
40. Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W, et al. Retinoid receptors: Pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 2000; 20: 1535-43.
41. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000; 21: 1271-9.
42. Simonson MS. Anti-AP-1 activity of all-trans retinoic acid in glomerular mesangial cells. Am J Physiol 1994; 267: F805-15.
43. Haxsen V, Adam-Stitah S, Ritz E, Wagner J. Retinoids inhibit the actions of angiotensin II on vascular smooth muscle cells. Circ Res 2001; 88: 637-44.
44. Miano JM, Kelly LA, Artacho CA, Nuckolls TA, Piantedosi R, Blaner WS. All-trans-retinoic acid reduces neointimal formation and promotes favorable geometric remodeling of the rat carotid artery after balloon withdrawal injury. Circulation 1998; 98: 1219-27.
45. Wen X, Li Y, Hu K, Dai C, Liu Y. Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol 2005; 167: 947-57.
46. Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001; 59: 2146-55.
47. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-8.
48. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 1525-38.
49. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 2004; 66: 68-76.
50. Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271: 15074-83.
51. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-49.
52. Zhang G, Kernan KA, Collins SJ, Cai X, López-Guisa JM, Degen JL, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: Role of plasmin-activated signals. J Am Soc Nephrol 2007; 18: 846-59.
53. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 1998; 91: 2005-9.
54. Border WA, Noble N. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001; 21: 563-72.
55. Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther 2007; 7: 293-304.
56. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 1998; 24: 174-80.